Although the diagnosis and therapy of HCC have being improved, the poor prognosis still remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with HCC tumor progression and may be useful as potential diagnosis or therapeutic targets.

SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identified from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular carcinoma associated antigens [4]

Serum antibody response to SMP30 in various patients using the methods of Western-blot and ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in the one with alpha-fetoprotein (AFP) negative

Inclusion Criteria:

1. Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or liver biopsy)
2. Adult patients
3. Both genders are eligible.
4. Informed consent obtained from subject or subject's legal representative

Exclusion Criteria:

1. Patient with other malignancies.
2. Patients with advanced comorbidities except for renal failure.
3. Prior chemotherapy

All patients will be subjected to the following:

• Detailed History taking.

• Physical examination.

• Routine laboratory investigations essential for diagnosis and follow up of patients including:

  1. Complete blood count (CBC).
  2. Chemistry profile: serum bilirubin-serum albumin-SGPT-SGOT.
  3. serum regucalcin(SMP30) antibodies using ELISA
  4. AFP level.

• Radiological assessment:

US, Triphasic CT to assess (tumor site, size, numbers, nodal metastases, distal metastases, portal vein invasion..)